SEARCH

SEARCH BY CITATION

References

  • 1
    Badia X, Mearin F, Balboa A, et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 2002; 20: 74958.
  • 2
    Camilleri M, Choi MG. Review article: Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 3
    Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 7508.
    Direct Link:
  • 4
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 64350.
  • 5
    Olden KW. Approach to the patient with severe, refractory irritable bowel syndrome. Curr Treat Options Gastroenterol 2003; 6: 3317.
  • 6
    Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003; 38: 10318.
  • 7
    Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 65460.
  • 8
    Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001; 13: 132732.
  • 9
    Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 101930 (Review).
  • 10
    Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96: 31229.
    Direct Link:
  • 11
    Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: toward a cost-effective management approach. Am J Manage Care 2001; 7(Suppl. 8): S26875.
  • 12
    American Gastroenterological Association. The burden of gastrointestinal diseases, 2001. Bethesda, MD: 136.
  • 13
    Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 92935.
  • 14
    Hahn BA, Yan S, Strassel S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 7781.
  • 15
    Jhingran P, Decker C, Watson M, Northcutt A, Ricci J-F. Alosetron reduces time lost from work in women with diarrhoea-predominant irritable bowel syndrome: data from phase III placebo-controlled clinical trials. Clin Drug Invest 2001; 21: 84352.
  • 16
    Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 150011.
  • 17
    Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 3918.
  • 18
    Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol 2001; 96(Suppl. 8): S5761.
  • 19
    Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 35365.
  • 20
    Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest 1996; 11: 27888.
  • 21
    Reilly MC, Lavin PT, Kahler KH, Pariser DM. Validation of the dermatology life quality index (DLQI) and the work productivity and activity impairment: chronic hand dermatitis questionnaire (WPAI-ChHD) in chronic hand dermatitis (ChHD). J Am Acad Dermatol 2003; 48: 12830.
  • 22
    Wahlqvist P, Carlsson J, Stålhammar N-O, Wiklund I. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) – results from a cross-sectional study. Value Health 2002; 5: 10613.
  • 23
    Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. Br J Urol Int 2003; 9: 1905.
  • 24
    Andréasson E, Svensson K, Berggren F. The validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): results from a web-based study. Value Health 2003; 6: 780.
  • 25
    Jacobs RJ, Davidson JR, Gupta S, Meyerhoff AS. The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manage Care 1997; 3: 118796.
  • 26
    Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once daily fexofenadine HCI improves quality of life and reduces work and activity impairment in patients with season allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 3117.
  • 27
    Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J. Effect of fexofenadine HCI on quality of life and work, classroom and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manage Care 1999; 5(Suppl. ): S23547.
  • 28
    Wahlqvist P, Bergenheim K, Långström G, Næsdal J. Resolution of upper gastrointestinal symptoms associated with chronic non-steroidal anti-inflammatory drug therapy has a positive impact on patient-reported productivity. Gut 2003; 52(Suppl. VI): A226.
  • 29
    Perrillo RP, Rothstein KD, Imperial JC, et al. Improved Work Productivity, Safety, and Quality of Life with Pegylated (40 kDa) Interferon ALFA-2a (PEGASYS®) Therapy in the Treatment of Chronic Hepatitis C (Poster presentations). Roche Laboratories, Nutley, NJ, 2000.
  • 30
    Dean B, Crawley J, Schmitt CM, Wong J, Ofman JJ. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003; 17: 130917.
  • 31
    Wittchen HU, Beloch E. The impact of social phobia on quality of life. Int Clin Psycopharmacol 1996; II: 1523.
  • 32
    Drossman DA. Rome II the Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, 2000.
  • 33
    Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care 2001; 39: 7285.
  • 34
    Lerner D, Rogers W, Chang H. Technical Report: Confidential Scoring the Work Limitations Questionnaire (WLQ©) Scales and the WLQ Index© for Estimating Work Productivity Loss. Revised April 22, 2003.
  • 35
    van Popppel MNM, de Ver HCW, Koes BW, Smid T, Bouter LM. Measuring sick leave: a comparison of self-reported data on sick leave and data from company records. Occup Med 2002; 52: 48590.
  • 36
    John G. Absentee estimates by employees and managers: divergent perspectives and self-serving behavior. J Appl Psychol 1994; 79: 22939.
  • 37
    Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88: 4152.
  • 38
    Kessler R, Barber C, Beck A, et al. The World Health Organization health and work performance questionnaire (HPQ). JOEM 2003; 45: 15674.
  • 39
    Day N, McKeown N, Wong M, Welch A, Bingham S. Epidemiological assessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol 2001; 30: 30917.
  • 40
    Santanello NC, Demuro-Mercon C, Davies G, et al. Validation of a pediatric asthma caregiver diary. J Allergy Clin Immunol 2000; 106: 8616.
  • 41
    Severens JL, Mulder J, Laheij R, Verbeek A. Precision in measuring absence from work as a basis for calculating productivity costs in the Netherlands. Soc Sci Med 2000; 51: 2439.
  • 42
    Greenhouse S. Altering of worker time cards spurs growing number of suits. New York Times, April 4, 2004.
  • 43
    Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 47781.
  • 44
    Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures’ responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38: 156880.
  • 45
    Ward MM. Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol 1994; 21: 1727
  • 46
    Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics 1999; 15: 24156 (Review).